A new trading day began on Tuesday, with Nektar Therapeutics (NASDAQ: NKTR) stock price down -4.84% from the previous day of trading, before settling in for the closing price of $25.84. NKTR’s price has ranged from $6.48 to $37.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 25.49% over the last five years. Meanwhile, its annual earnings per share averaged -19.62%. With a float of $11.96 million, this company’s outstanding shares have now reached $12.41 million.
The firm has a total of 61 workers. Let’s measure their productivity. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -19.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.75% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Here are Nektar Therapeutics’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.53, a number that is poised to hit -2.96 in the next quarter and is forecasted to reach -12.11 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 8.85 million was better than the volume posted last year of 0.85 million. As of the previous 9 days, the stock’s Stochastic %D was 58.96%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 58.65%, which indicates a significant increase from 56.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 413.42% in the past 14 days, which was higher than the 189.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.15, while its 200-day Moving Average is $14.37. Now, the first resistance to watch is $25.49. This is followed by the second major resistance level at $26.39. The third major resistance level sits at $27.04. If the price goes on to break the first support level at $23.94, it is likely to go to the next support level at $23.29. Should the price break the second support level, the third support level stands at $22.39.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
With a market capitalization of 305.08 million, the company has a total of 12,407K Shares Outstanding. Currently, annual sales are 98,430 K while annual income is -118,960 K. The company’s previous quarter sales were 10,460 K while its latest quarter income was -50,880 K.
